Investment Rating - The report maintains an "Outperform" rating for Hutchmed (China) Limited with a target price of HK$38.11, reflecting a potential upside from the current price of HK$22.18 [2][25]. Core Insights - Hutchmed reported a total revenue of USD 549 million for FY25, a decrease of 13% year-on-year, with oncology/immunology combined revenue at USD 290 million, down 21% year-on-year. The decline was attributed to a high base effect from a previous milestone payment and a drop in domestic sales of key products [3][18]. - The management expects a recovery in sales for FY26, projecting oncology/immunology revenue between USD 330 million and USD 450 million, which includes potential income from licensing the ATTC platform [3][19]. - The company is focusing on the development of its Antibody-Targeted Toxin Conjugate (ATTC) platform, with two products currently in global clinical development [6][19]. Financial Performance - For FY25, Hutchmed's R&D expenses were USD 150 million, down 30% year-on-year, while SG&A expenses were USD 100 million, a decrease of 9% year-on-year. The net profit attributable to shareholders reached USD 460 million, boosted by a one-time gain from the sale of a subsidiary [3][18]. - The company had cash and cash equivalents of USD 1.37 billion at the end of FY25, indicating a strong cash position [3][18]. Product Performance - Fruquintinib (ex-China) sales reached USD 370 million, up 26% year-on-year, driven by growth in the Japanese market and improved reimbursement coverage in Europe. However, domestic sales of Fruquintinib (China) fell to USD 76.9 million, down 11% year-on-year, impacted by intensified competition [19][23]. - The report highlights that the sales of core products in China showed signs of improvement in the second half of FY25 compared to the first half, with Fruquintinib (China) revenue increasing by 29% quarter-on-quarter [19][23]. Clinical Development - HMPL-A251, a first-in-class ATTC targeting HER2, has shown promising anti-tumor activity comparable to existing therapies and is currently in a global Phase I/IIa clinical trial for advanced solid tumors [20][24]. - HMPL-A580, another ATTC candidate targeting EGFR, has also entered clinical development, with a global Phase I trial initiated in March 2026 [21][22]. Valuation - The revenue forecasts for FY26 and FY27 have been adjusted to USD 653 million and USD 699 million, respectively, reflecting the competitive landscape. The net profit forecasts for the same periods have been adjusted to USD 10 million and USD 32 million [9][25]. - The valuation is based on a DCF model with a WACC of 9.2% and a perpetual growth rate of 3.0%, leading to a target price of HK$38.11 per share [9][25].
和黄医药（00013）：2025年业绩回顾：收入26年有望复苏，关注ATTC平台长期价值